DuPont de Nemours reports Q1 2026 results on May 5 with analysts trimming targets and the stock trading well below consensus fair value.
The most telling positioning signal is in the analyst community. Since the last earnings beat in February — when the stock jumped over 9% in a single session — several key firms have quietly walked back their price targets. RBC Capital lowered its target to $56 from $60 last week, while B of A Securities trimmed to $47, just slightly above the current price of $46.24. Citigroup also cut to $56. The direction of travel is clear: the Street remains broadly positive, with a consensus target near $55.40 implying roughly 21% upside, but conviction has softened in the run-up to the print.
Short sellers offer no particular challenge to that constructive view. At 2.4% of the free float, short interest is modest — and it fell roughly 9% over the past week after spiking in mid-April when shares sold off with the broader market. Borrowing costs are well below 0.4%, and borrow availability is extremely loose, pointing to no meaningful squeeze pressure or bearish urgency in the lending market. The ORTEX short score of 32.7 is unremarkable, sitting in the lower-mid range.
Options sentiment is slightly more defensive than usual, though not dramatically so. The put/call ratio nudged up to 0.47, about 1.2 standard deviations above its 20-day average of 0.43. That's a modest lean toward protection but far from the extreme hedging seen at other points in the past year. The RSI at 47 corroborates the neutral technical backdrop — the stock is neither overbought nor significantly oversold heading into the event.
The bull case centres on Healthcare and Water segment momentum, where high-single-digit growth in medical packaging and biopharma solutions has driven recent outperformance. Bears point to lingering execution risk in electronics and construction, where recovery has been uneven, and to the stock's 8% decline from February post-earnings highs despite that strong Q4 beat. Institutional holders remain well-positioned — Vanguard, BlackRock and State Street together control nearly 25% of shares, with Invesco adding roughly 3 million shares as recently as March 31. Insider activity in February, including sells by CEO Lori Koch and Executive Chairman Edward Breen at prices around $50, now looks more prescient given the stock's drift lower.
The May 5 print will test whether DD can demonstrate that its Healthcare and Electronics growth engines are durable enough to justify a re-rating back toward the $55 analyst consensus — or whether persistent segment weakness keeps the stock rangebound despite a constructive macro read-through.
See the live data behind this article on ORTEX.
Open DD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
